Treatment progress of chronic lymphocytic leukemia
10.3760/cma.j.cn115356-20200229-00054
- VernacularTitle:慢性淋巴细胞白血病治疗进展
- Author:
Shijia CHENG
1
;
Hongxia MA
;
Yu WANG
Author Information
1. 郑州市第三人民医院血液科 450000
- From:
Journal of Leukemia & Lymphoma
2020;29(6):381-384
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia (CLL) is a highly heterogeneous disease, and combined chemotherapies symbolized by rituximab + fludarabine + cyclophosphamide have made great achievements in the era of traditional immunochemotherapy. However, for the patients with high genetic risk, relapsed and refractory patients as well as the elderly patients who cannot tolerate it, the therapeutic effect of this regimen is not good. The new drugs represented by BTK inhibitors have solved the above problems to a certain extent, and it is hopeful to move into the chemotherapy-free age of CLL treatment and bring the possibility of drug withdrawal. This article reviews the progress of CLL treatment.
